TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Sanofi ( (SNY) ) just unveiled an update.
In November 2025, Sanofi announced significant advancements in its pharmaceutical offerings. On November 7, 2025, Sanofi, in collaboration with Regeneron, revealed that their drug Dupixent met all primary and secondary endpoints in a pivotal phase 3 study for allergic fungal rhinosinusitis (AFRS), leading to the acceptance of a supplemental biologics license application for FDA priority review. This marks a potential new indication for Dupixent, which could become the first treatment specifically approved for AFRS. Additionally, on November 14, 2025, Sanofi’s drug Teizeild received a recommendation for EU approval for patients with stage 2 type 1 diabetes. These developments highlight Sanofi’s ongoing commitment to expanding its treatment portfolio and enhancing its market position in the pharmaceutical industry.
The most recent analyst rating on (SNY) stock is a Buy with a $55.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page.
Spark’s Take on SNY Stock
According to Spark, TipRanks’ AI Analyst, SNY is a Outperform.
Sanofi’s overall stock score is driven by strong earnings call performance and attractive valuation. Financial stability and solid profitability support the score, despite some challenges in cash flow and revenue growth. Technical analysis indicates a stable market position, contributing to a positive outlook.
To see Spark’s full report on SNY stock, click here.
More about Sanofi
Sanofi is a global healthcare company based in Paris, France, specializing in the development and distribution of pharmaceutical products. The company focuses on a wide range of therapeutic areas including diabetes, cardiovascular diseases, and immunology, with a strong emphasis on innovative treatments for chronic conditions.
Average Trading Volume: 2,977,436
Technical Sentiment Signal: Strong Buy
Current Market Cap: $126.6B
For an in-depth examination of SNY stock, go to TipRanks’ Overview page.